SecBot SecBot
8-K/A ·Filed Nov 12, 2026

LSTA

LISATA THERAPEUTICS, INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed10d 1h ago SEC0001140361-26-043233
8-K with no item list reported
Actionable Insight • Neutral

The filing provides audited baseline financials for the acquired Marea business. Monitor the combined company's cash runway given the $225M PIPE and $31M Marea cash at June 30, 2026. Key catalysts are clinical data for MAR001 (severe hypertriglyceridemia) and MAR002 (acromegaly). The Series C preferred stock conversion requires stockholder approval; watch for the proxy vote timeline.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

LSTA drug pipeline →

MAR001/005

● Neutral Named in this 8-K/A
Impact
Phase
Phase 2b
Time to market
At least 3-5 years — Phase 2b data expected Q4 2027, followed by potential Phase 3 trials and regulatory filing
Next catalyst
None dated

What to watchThe November 9 stockholder vote is the immediate binary catalyst, failure to approve Series C conversion and reverse split could trigger cash settlement obligations and Nasdaq delisting risk. For MAR001/005 specifically, Phase 2b topline data is not expected until Q4 2027, over a year away. The extreme dilution (~2.39% legacy ownership) means LSTA stock is now effectively a proxy for Marea Therapeutics' pipeline, but with corporate governance overhangs that need resolving first.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.28
T+0 close · Nov 12, 2026 · via day close
Latest settled
−28.91%
T+5 · $0.9100
Vs SPY
−23.46%
α at T+5
Next horizon
T+20
in 19d
  1. T+0 · Nov 12 $1.28entry
  2. T+1 · 9d ago −5.47%α −5.11% · $1.21
  3. T+5 · 3d ago −28.91%α −23.46% · $0.9100
  4. T+6 · todayOpen
  5. T+20 · in 19d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lisata Therapeutics filed an 8-K/A to provide audited financial statements of Marea Therapeutics (acquired on September 17, 2026) and unaudited pro forma combined financials. The acquisition was structured as a reverse merger: former Marea equity holders own ~59.5% of the combined company on a fully-diluted basis, legacy Lisata holders ~2.4%, and PIPE investors ~38.1%. The combined entity has a $12M market cap with no approved products and substantial operating losses.

Key Facts

  • Lisata acquired Marea on September 17, 2026 in a reverse merger; former Marea holders own ~59.5% of combined entity on a fully-diluted basis.
  • Concurrent PIPE raised ~$225M gross via Series C non-voting convertible preferred stock.
  • Marea's audited combined financials show net losses of $62.6M (2025) and $43.9M (2024); accumulated deficit of $141.3M as of Dec 31, 2025.
  • Marea's cash burn was $51.2M (2025) and $44.6M in H1 2026; cash balance fell from $75.3M (Dec 2025) to $31.0M (Jun 2026).
  • Marea had a going concern qualification; $65M SAFE was converted to equity pre-merger.
  • Pro forma combined net loss was $62.1M for FY2025 and $49.8M for H1 2026.
  • Estimated purchase price was $377.8M; $292.9M allocated to IPR&D (MAR001/005, MAR002, MAR003) and $44.9M to goodwill.
  • Lisata's market cap is $12M with a 6.4% normal daily move.

Financial Impact

Marea's net losses of $62.6M (FY2025) and $52.2M (H1 2026); pro forma combined net loss of $62.1M (FY2025) and $49.8M (H1 2026). PIPE raised $225M gross. Purchase price $377.8M.

revenuenet losscashdilutiongoodwillIPR&D

Risk Factors

  • Combined entity has no approved products and substantial operating losses; going concern risk persists despite PIPE proceeds.
  • Marea's pre-acquisition going concern qualification and rapid cash burn ($44.6M in H1 2026) highlight execution risk.
  • Series C preferred stock conversion requires stockholder approval; failure could trigger cash settlement obligations.
  • Preliminary purchase price allocation is subject to change; final IPR&D and goodwill values may differ materially.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K/A Filing (Primary)0001140361-26-043233
Document: ef20085283_ex99-5.htm0001140361-26-043233
Document: ef20085283_ex99-4.htm0001140361-26-043233
Document: ef20085283_8ka.htm0001140361-26-043233

Track record

21 reports on LSTA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 19, 20262d ago S-3/A Bearish 6/10 Entry $0.9507 settles Feb 19
  2. Nov 19, 20262d ago 8-K/A Neutral 3/10 Entry $0.9507 settles Feb 19
  3. Nov 19, 20262d ago 8-K Bearish 5/10 Entry $0.9100 settles Feb 18
  4. Nov 19, 20262d ago Press Release Neutral 4/10 Entry $0.9100 settles Feb 18
  5. Nov 12, 20269d ago S-3 Bearish 6/10 Entry $1.21 settles Feb 11
  6. Nov 12, 202610d ago 8-K/A Neutral 4/10 Viewing Entry $1.28 settles Feb 10
  7. Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $1.02 settles Feb 8
  8. Nov 9, 202612d ago 8-K Neutral 4/10 Entry $1.02 settles Feb 8
  9. Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
  10. Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
Showing 10 of 21

US Market Status

Market Closed · Opens Mon (26h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026